Influenza

Clinics in Laboratory Medicine

Volumn 22, Issue 4, 2002, Pages 863-882

  Harper, Scott ^a,b   Klimov, Alexander ^a   Uyeki, Timothy ^a   Fukuda, Keiji ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; VIRUS RNA; INFLUENZA VACCINE;

EPIDEMIC; HUMAN; INFLUENZA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROLOGY; UNITED STATES; VACCINATION; VIRUS ISOLATION; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RNA, VIRAL; VACCINATION;

EID: 1842869279     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00022-7     Document Type: Review

References (58)

1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid Mortal Weekly Rep 2001;50(RR-04):1-63.
2. Neuzil KM, Reed GW, Mitchel EF, et al. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999;281:901-7.
3. Cox NJ, Kawaoka Y. Orthomyxoviruses: Influenza. In: Collier L, Sussman M, Balows A, editors. Topley & Wilson's Microbiology & Microbial Infections. 9th Edition. London: Edward Arnold Publishing; 1998.
4. Susser M, Adelstein A. An introduction to the work of William Farr. Am J Epidemiol 1975;101:469-76.
5. Noble G. Epidemiological and clinical aspects of influenza. In: Beare AS, editor. Basic and Applied Influenza Research. Boca Raton (FL): CRC Press; 1982. p. 12-50.
6. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, et al, editor. Virology. 2nd Edition. New York: Raven Press; 1990. p. 1091-152.
7. Kawaoka Y, Krauss S, Webster R. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989;63:4603-8.
8. Taubenberger J, Reid A, Krafft A, et al. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997;275:1793-6.
9. Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with fatal respiratory illness. Science 1998;279:393-6.
10. Yuen K, Chan P, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
11. Treanor JJ. Influenza. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th Edition. Philadelphia: Churchill Livingstone; 2000. p. 1823-49.
12. Zambon M, Hays J, Webster A, et al. Diagnosis of influenza in the community: Relationship of clinical diagnosis to confirmed virological, serologic, or molecular detection of influenza. Arch Intern Med 2001;161:2116-22.
13. Stevens KM. The pathophysiology of influenza pneumonia in 1918. Perspect Biol Med 1981;25:115-25.
14. Hayase Y, Tobita K. Influenza virus and neurological diseases. Psychiatry Clin Neurosci 1997;51:181-4.
15. Sion M, Hatzitolios A, Toulis E, et al. Toxic shock syndrome complicating influenza A infection: A two-case report with one case of bacteremia and endocarditis. Intensive Care Med 2001;27:443.
16. Fujimoto S, Kobayashi M, Uemura O, et al. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis. Lancet 1998;352:873-5.
17. Shinjoh M, Bamba M, Jozaki K, et al. Influenza A-associated encephalopathy with bilateral thalamic necrosis in Japan. Clin Infect Dis 2000;31:611-3.
18. Togashi T, Matsuzono Y, Marita M. Epidemiology of influenza-associated encephalitis-encephalopathy in Hokkaido, the northernmost island of Japan. Pediatr Int 2000;42:192-6.
19. Waris M, Ziegler T, Kivivirta M, et al. Rapid detection of respiratory syncitial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies. J Clin Microbiol 1990;28:1159-62.
20. Espy M, Smith T, Harmon M, et al. Rapid detection of influenza virus by shell vial assay with monoclonal antibodies. J Clin Microbiol 1986;24:677-9.
21. Daisy J, Lief F, Friedman H. Rapid diagnosis of influenza A infection by direct immunofluorescence of nasopharyngeal aspirates in adults. J Clin Microbiol 1979;9:688-92.
22. Medical letter. Rapid diagnostic tests for influenza. Med Lett Drugs Ther 1999;41:121-2.
23. Waner J, Todd S, Shalaby H, et al. Comparison of Directogen Flu-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus. J Clin Microbiol 1991;29:479-82.
24. Munoz F, Galasso G, Gwaltney J, et al. Current research on influenza and other respiratory viruses: II. International symposium. Antiviral Res 2000;46:91-124.
25. Coonrod J, Betts R, Lnnemann C, et al. Etiologic diagnosis of influenza A virus by enzymatic radioimmunoassay. J Clin Microbiol 1984;19:361-5.
26. Walls H, Johansson K, Harmon M, et al. Time-resolved fluoroimmunoassay with monoclonal antibodies for rapid diagnosis of influenza infections. J Clin Microbiol 1986;24:907-12.
27. Harmon M, Pawlik K. Enzyme immunoassay for direct detection of influenza type A and adenovirus antigens in clinical specimens. J Clin Microbiol 1982;15:5-11.
28. Stockton J, Ellis J, Saville M, et al. Multiplex PCR for typing and subtyping influenza and respiratory syncitial viruses. J Clin Microbiol 1998;36:2990-5.
29. Liolios L, Jenney A, Spelman D, et al. Comparison of multiplex reverse transcription-PCR-enzyme hybridization assay with conventional viral culture and immunofluorescence techniques for the detection of seven viral respiratory pathogens. J Clin Micro 2001;39:2779-83.
30. Kehl S, Henrickson K, Hua W, et al. Evaluation of the Hexaplex assay for detection of respiratory viruses in children. J Clin Micro 2001;39:1696-701.
31. Fan J, Henrickson K, Savatshi L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza virus A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription - Polymerase chain reaction - Enzyme hybridization assay (Hexaplex). Clin Inf Dis 1998;26:1397-402.
32. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
33. Kilbourne ED, Arden NH. Inactivated influenza vaccines. In: Plotkin M, Orenstein W, editors. Vaccines. 3rd Edition. Philadelphia: Harcourt; 1999. p. 531-52.
34. Palache A. Influenza vaccines: A reappraisal of their use. Drugs 1997;54:841-56.
35. Mullooly J, Bennett M, Hornbrook M, et al. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-52.
36. Nichol K, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-76.
37. Patriarca P, Weber J, Parker R, et al. Efficacy of influenza vaccine in nursing homes: Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985;253:1136-9.
38. Arden NH, Patriarca P, Kendal A. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal A, Patriarca P, editors. Options for the Control of Influenza. New York: Alan R. Liss, Inc.; 1986. p. 155-68.
39. Rudenko LG, Arden NH, Grigorieva E, et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine 2001;19:308-18.
40. Ropper AH. Guillain-Barré syndrome. N Engl J Med 1992;326:1130-6.
41. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: Results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133:940-51.
42. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
43. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
44. Chen R, Kent J, Rhodes P, et al. Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the United States, 1990-1991 [abstract 040]. Post Marketing Surveillance 1992;6:5-6.
45. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981;304:1557-61.
46. Kaplan JE, Katona P, Hurwitz ES, et al. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. JAMA 1982;248:698-700.
47. Douglas RG. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-50.
48. Centers for Disease Control and Prevention. Neuraminidase inhibitors for treatment of influenza A and B infections. Morbid Mortal Weekly Rep 1999;48(RR-14).
49. Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957-1030.
50. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantidine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
51. Monto A, Arden N. Implications of viral resistance to amantadine in control of influenza A. Clin Infect Dis 1992;15:362-7.
52. Treanor J, Hayden F, Vrooman P, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. JAMA 2000;283:1016-24.
53. Nicholson K, Aoki F, Osterhaus A, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomized controlled trial. Lancet 2000;355:1845-50.
54. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminadase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80.
55. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections. Lancet 1998;352:1877-81.
56. Henney J. Revised labeling for zanamivir. JAMA 2000;284:1234.
57. Gubareva L, Matrosovich M, Brenner M, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.
58. Gubavera L, Kaiser L, Matrosovich M. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001;183:523-31.